Please use this identifier to cite or link to this item:
DC FieldValue
dc.title68Ga-NOTA-Evans Blue PET/CT findings in lymphangioleiomyomatosis compared with 99mTC-ASC lymphoscintigraphy: a prospective study
dc.contributor.authorHou, Guozhu
dc.contributor.authorJiang, Yuanyuan
dc.contributor.authorXu, Wenshuai
dc.contributor.authorZhu, Zhaohui
dc.contributor.authorHuo, Li
dc.contributor.authorChen, Xiaoyuan
dc.contributor.authorLi, Fang
dc.contributor.authorXu, Kai-Feng
dc.contributor.authorCheng, Wuying
dc.identifier.citationHou, Guozhu, Jiang, Yuanyuan, Xu, Wenshuai, Zhu, Zhaohui, Huo, Li, Chen, Xiaoyuan, Li, Fang, Xu, Kai-Feng, Cheng, Wuying (2021-06-16). 68Ga-NOTA-Evans Blue PET/CT findings in lymphangioleiomyomatosis compared with 99mTC-ASC lymphoscintigraphy: a prospective study. Orphanet Journal of Rare Diseases 16 (1) : 279. ScholarBank@NUS Repository.
dc.description.abstractBackground: Lymphangioleiomyomatosis (LAM) is a rare multisystem disease characterized by cystic lung disease and extrapulmonary manifestations, including lymphatic system disorder. The objective of this study was to investigate the findings of 68Ga-NOTA-Evans Blue (NEB) PET/CT in LAM and compare it with that of 99mTc-ASC lymphoscintigraphy. Methods: Ten patients diagnosed with LAM according to the American Thoracic Society/Japanese Respiratory Society guidelines for LAM were recruited in this study. PET/CT acquisition was performed at 20 to 40 min after subcutaneous injection of 68Ga-NEB into the first interdigital spaces of both feet (0.3 ml, 37 MBq/foot). All subjects also underwent 99mTc-antimony sulfide colloid (ASC) lymphoscintigraphy within a week for comparison. Results: 68Ga-NEB PET/CT displayed various lymphatic system abnormalities in 10 (100%) of 10 patients. These included pulmonary lymphatic abnormalities in 10 (100%) of 10 patients, enlarged lymph nodes in 5 (50%), lymphangioleiomyomas in 2 (20%), dilation of the lumbar trunk and/or iliac lymph vessels in 5 (50%), thoracic duct dilation in 2 (20%), chylous effusion in 1 (10%). For pulmonary lymphatic abnormalities, the positive rates of 68Ga-NEB PET/CT and 99mTc-ASC lymphoscintigraphy were 100% (10/10) and 10% (1/10), respectively (P < 0.001). As for the 7 patients with extrapulmonary lymphatic manifestations, 68Ga-NEB PET/CT also presented more information than 99mTc-ASC lymphoscintigraphy. Conclusion: 68Ga-NEB PET/CT visualized pulmonary lymphatic abnormality and displayed extrapulmonary lymphatic system disorders of LAM, and might play a role in the diagnosis and evaluation of the disease. 68Ga-NEB PET/CT is advantageous over conventional 99mTc-ASC lymphoscintigraphy in LAM by providing more detailed information of lymphatic dysfunction. © 2021, The Author(s).
dc.publisherBioMed Central Ltd
dc.rightsAttribution 4.0 International
dc.sourceScopus OA2021
dc.subject68Ga-NOTA-Evans Blue (68Ga-NEB)
dc.contributor.departmentDEPT OF DIAGNOSTIC RADIOLOGY
dc.description.sourcetitleOrphanet Journal of Rare Diseases
Appears in Collections:Staff Publications

Show simple item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
10_1186_s13023-021-01895-1.pdf1.39 MBAdobe PDF




checked on Jan 30, 2023

Page view(s)

checked on Jan 26, 2023

Google ScholarTM



This item is licensed under a Creative Commons License Creative Commons